Every week at Nirvana Clinic in Greater Noida, I see patients holding two pamphlets — one for Mounjaro, one for Wegovy — asking the same question: "Doctor, which one should I take?"

If you read the medical literature alone, the answer looks simple. Mounjaro (tirzepatide) outperforms Wegovy (semaglutide) on weight loss by a meaningful margin in the SURMOUNT-5 head-to-head trial. End of story.

But that is not the question my patients are really asking. Once we sit down and look at their 12 to 18 month treatment plan, the conversation turns — almost every single time — to cost. And the cost gap between these two drugs in India right now is wider than most patients realise, because tirzepatide is still patented and semaglutide is not.

This article gives you the honest clinical comparison and the honest financial comparison. Both matter. For most Indian patients, the financial picture is what actually decides which medication is right for them.

Why This Comparison Looks Different in India Right Now

If you read articles written for the US or UK market, both drugs cost roughly the same to the patient — somewhere between $1,000 and $1,350 per month at list price. The choice there really is mostly about clinical effectiveness and insurance coverage.

India is a completely different market in 2026, and three things have changed it:

• March 20, 2026 — Semaglutide patent expired in India. Over 40 generic brands have launched. Vials start at ₹1,290/month; pen formats from ₹4,500/month. This is roughly 4% of the equivalent Wegovy price in the US.
• April 1, 2026 — Novo Nordisk slashed Ozempic prices by up to 36% and Wegovy by up to 48% to compete with generics. Wegovy 0.25 mg dropped from ₹10,848 to ₹5,660/month overnight.
• Novo Nordisk's "second brand" strategy. Rather than fight generics on price alone, Novo Nordisk has partnered with two large Indian pharma companies to launch second brands of its own semaglutide — same molecule, same Novo manufacturing, but distributed by partners with deeper reach into tier-2 and tier-3 cities. Poviztra (Wegovy via Emcure, launched December 2025) and Extensior (Ozempic via Abbott India, launched February 2026) are the result. After their own April 2026 price cuts, these second brands are now among the most affordable Novo-quality semaglutide options in India.
• Mounjaro remains untouched. Eli Lilly's tirzepatide is under patent protection until approximately 2036. There has been no price reduction. As of late 2025, Mounjaro was already the top-selling drug in Indian pharma at ₹100 crore monthly sales. There is no commercial pressure for Lilly to cut prices yet.

The result: a price gap that didn't exist a year ago, and almost certainly won't exist 7–10 years from now (when tirzepatide goes generic). But right now, in 2026, it is the single biggest practical factor in this decision.

The Clinical Comparison — What SURMOUNT-5 Actually Showed

Let me give you the clinical picture first, then we will weigh it against cost.

SURMOUNT-5 was the first proper head-to-head trial directly comparing tirzepatide (Mounjaro/Zepbound) and semaglutide (Wegovy) for weight loss. Published in the New England Journal of Medicine in May 2025, it randomised 751 adults with obesity (but without diabetes) to the maximum tolerated dose of each drug over 72 weeks.

The takeaway from the trial: tirzepatide delivers about 47% more mean weight loss than semaglutide when both are dosed to maximum tolerance. And — counterintuitively — it was actually better tolerated, with fewer patients dropping out due to GI side effects.

So clinically, Mounjaro is the more powerful drug. That part is not in dispute.

The Real Decision Factor: Cost Over 12–18 Months

Here is the conversation I have with every patient who walks into my clinic considering GLP-1 therapy. This is not a 3-month treatment. It is, at minimum, a 12–18 month commitment, and for many patients an indefinite one.

Why? Because stopping the medication too early leads to weight regain in 70–82% of patients within 12 months. The drug is treating a chronic condition. The commitment is long.

So when we evaluate cost, we should not look at one month's MRP. We should look at the full treatment course.

Let me put it simply. Choosing Mounjaro over Wegovy for a 12-month course costs an additional ~₹1,12,572. But the real eye-opener is Poviztra — Emcure's distributed version of Novo Nordisk's Wegovy, same molecule and same manufacturer. At maximum dose, Poviztra costs roughly ₹2,01,384 less than Mounjaro over 12 months, and around ₹88,812 less than Wegovy itself over the same period. Over 18 months — a more realistic commitment — the Poviztra-vs-Mounjaro gap widens to roughly ₹3,02,076.

Choosing Mounjaro over generic semaglutide costs ~₹2,93,892 more over 12 months. That is more than a small car.

For most Indian patients I see, that is the entire deciding factor — and it should be discussed openly, not avoided.

So Does Wegovy Actually Work Well Enough?

This is the crucial question, and I want to answer it honestly.

Wegovy at the 2.4 mg maintenance dose delivers an average weight loss of 14.9% over 68 weeks in the STEP-1 trial. For a 100 kg patient, that is roughly 15 kg. For most patients with obesity-related comorbidities — fatty liver, prediabetes, PCOS, hypertension — that magnitude of weight loss is clinically transformative. We see:

• HbA1c reductions of 1.0–1.5% (often enough to reverse prediabetes)
• Significant reduction in liver fat and fibroscan scores
• Improved menstrual regularity and ovulation in PCOS
• Blood pressure improvements averaging 5–8 mmHg
• Substantial cardiovascular risk reduction (SELECT trial data)

Wegovy also has two unique advantages over Mounjaro that often get glossed over:

1. Cardiovascular outcomes data. The SELECT trial demonstrated a 20% reduction in major adverse cardiac events in patients with established cardiovascular disease. Semaglutide has this evidence. Tirzepatide does not (yet).
2. MASH / fatty liver approval. Wegovy is now approved in the US for MASH (metabolic dysfunction-associated steatohepatitis) with moderate to advanced fibrosis. For patients whose primary issue is fatty liver, this is a meaningful clinical edge.

For a patient with cardiovascular risk factors, a history of heart disease, or significant fatty liver — Wegovy's slightly lower weight-loss percentage may be more than compensated for by its proven organ-protection benefits.

When Mounjaro Is Worth the Premium

I do not want to write an article that talks every patient out of Mounjaro. There are specific clinical scenarios where the extra ₹1.5–2 lakh is genuinely justified, and you should know what they are.

1. BMI ≥ 40 (Severe / Class III Obesity)

If you need to lose 35+ kg to reach a healthy BMI, the additional weight-loss potential of tirzepatide becomes mathematically meaningful. The 6–7% efficacy gap from SURMOUNT-5 translates to ~7–10 extra kg of weight loss. At this severity, that is clinically significant.

2. Co-existing Type 2 Diabetes Requiring Aggressive HbA1c Control

Mounjaro produces HbA1c reductions averaging 2.0–2.5%, compared to 1.5–1.8% with semaglutide. If your HbA1c is 9.5%+ and you need to come down fast — particularly if you are on insulin — tirzepatide's dual GIP+GLP-1 mechanism offers a clinically superior glycaemic effect.

3. Failed Response or Plateau on Semaglutide

About 15–20% of patients are "low responders" to semaglutide — they tolerate it fine but lose less than 5% of body weight at maximum dose. These patients often respond well to switching to tirzepatide, because the additional GIP receptor activation works through a partially different pathway.

4. Severe Insulin Resistance / Metabolic Syndrome

The dual mechanism appears to address insulin resistance more aggressively than GLP-1 monotherapy. In my practice, patients with very high HOMA-IR scores or significant PCOD/metabolic syndrome often see better outcomes on tirzepatide.

5. Cost Is Not a Constraint

For patients where the additional ₹1.5–2 lakh per year is genuinely insignificant, there is no reason not to choose the more powerful drug. Mounjaro is the better molecule — full stop. The question is only whether the value-for-money is right for your specific situation.

Side-by-Side: The Full Comparison

The "Second Brand" Landscape: Poviztra, Extensior, and Yurpeak

Most articles comparing Mounjaro and Wegovy in India completely miss what has become — quietly — the most important development in the GLP-1 market here. In a span of about 14 months, both Novo Nordisk and Eli Lilly have signed distribution partnerships with major Indian pharma companies to launch second brands of their own drugs.

The strategy is simple. Novo and Lilly keep the manufacturing (so quality stays unchanged), but hand over the marketing and distribution to a partner with deeper Indian reach. For patients, this means access to the original Novo or Lilly molecule, at a partner's distribution channel, often at a lower price than the parent brand.

Three brands now matter:

Poviztra (Emcure) — Novo's Second Brand of Wegovy

Launched in December 2025 by Emcure Pharmaceuticals, Poviztra is the same 2.4 mg semaglutide injection as Wegovy — manufactured by Novo Nordisk, identical molecule, identical pen device, identical clinical evidence (STEP and SELECT trials). The only difference is the brand label and Emcure's distribution network, which reaches deeper into tier-2 and tier-3 Indian cities than Novo's own footprint.

After Emcure's April 2026 price cut of up to 55%, the pricing now stands at:

• 0.25 mg starting dose: ₹3,999/month (Wegovy: ₹5,660/month)
• 2.4 mg maintenance dose: ₹8,999/month (Wegovy: ₹16,400/month)

This is the single biggest practical change for cost-conscious patients in 2026. Poviztra at the 2.4 mg maintenance dose costs roughly 45% less than branded Wegovy, while delivering the exact same clinical outcomes. It carries the same STEP-1 (14.9% weight loss) and SELECT (20% MACE reduction) evidence base, because it is the same molecule.

Extensior (Abbott India) — Novo's Second Brand of Ozempic

Announced in February 2026 and rolling out across India, Extensior is the Abbott-distributed version of Ozempic — Novo Nordisk's lower-dose semaglutide approved for Type 2 diabetes. It is available in the same three strengths as Ozempic (0.25 mg, 0.5 mg, and 1 mg weekly), in the same pre-filled FlexTouch pen format, manufactured by Novo.

Abbott has not formally disclosed the full Extensior price list at the time of writing, but multiple sources indicate it will be priced competitively against the post-cut Ozempic range of ₹5,660–8,800/month and against generic semaglutide entrants. Abbott's strategic advantage is its enormous Indian distribution network — particularly into endocrinology and internal medicine specialist clinics — and its position as a "trusted brand" in diabetes care, complementing its CGM (continuous glucose monitor) and diabetes nutrition portfolio.

For patients who specifically want Novo-quality semaglutide for Type 2 diabetes and want access through Abbott's specialist channels (often more reliable in non-metro areas), Extensior is the right pick. The molecule and the trial evidence are exactly the same as Ozempic.

Yurpeak (Cipla) — Lilly's Second Brand of Mounjaro

Eli Lilly has followed a similar strategy on the tirzepatide side. Yurpeak, launched December 2025 through an exclusive Cipla partnership, is the same molecule as Mounjaro (tirzepatide), manufactured in the same Lilly facilities, priced identically (₹13,125–25,781/month). The differentiator is Cipla's pharmacy network — among the deepest in India — making Yurpeak easier to source in cities and towns where Mounjaro stocks may be inconsistent.

Unlike Poviztra, however, Yurpeak is not cheaper than Mounjaro. Tirzepatide is still on patent, and Lilly has no reason to discount through its distribution partner. Yurpeak's value is availability, not affordability.

The Honest Decision Framework

Here is the framework I use in clinic. Find your situation below.

Choose Wegovy (or Poviztra, or generic semaglutide) if:

• Your BMI is 27–40 (most overweight and obese patients)
• You need to lose 10–25 kg over 12–18 months
• You have cardiovascular risk factors or established heart disease
• You have fatty liver as a primary concern
• Cost over a 12–18 month treatment course is a meaningful factor (in which case Poviztra is now the most affordable Novo-quality option)
• You want a delivery format that is well-established with pen autoinjector ease

Choose Mounjaro (or Yurpeak) if:

• Your BMI is ≥40 (class III obesity)
• You have Type 2 diabetes with HbA1c ≥9.5% needing aggressive control
• You have already tried semaglutide and were a low responder
• You have severe insulin resistance / advanced metabolic syndrome
• Cost is genuinely not a constraint for your situation
• You want the most powerful weight-loss molecule available

Consider Generic Semaglutide if:

• Cost is a serious constraint but you still need GLP-1 therapy
• You are comfortable with vial-and-syringe administration (or your doctor's nurse can train you)
• You will be under supervision from a qualified physician to ensure quality sourcing

For more on the generic options and what to look for, see my detailed Generic Semaglutide India 2026 Price Guide.

What I Tell My Patients in the Consultation

When a patient sits across from me weighing Mounjaro versus Wegovy, here is the conversation I actually have, in roughly this order:

1. What is your treatment goal in numbers? "I want to lose weight" is not enough. Are we targeting 10 kg? 25 kg? 40 kg? This determines whether the efficacy gap between the drugs is clinically meaningful or just statistically meaningful.

2. What is your realistic treatment horizon? If you plan to be on therapy for 6 months and then stop, you will likely regain most of the weight regardless of which drug you choose. If you plan to commit to 18–24 months minimum with proper supervision, cost becomes a major factor.

3. What is your monthly medication budget without strain? I ask this directly. There is no point prescribing Mounjaro if a patient will quit at month 4 because the bill became unsustainable. Half-finished GLP-1 therapy is worse than not starting at all — you get the cost without the lasting benefit.

4. What other risk factors do we need to address? Cardiovascular disease? Fatty liver? Diabetes? These tilt the decision in subtle ways the comparison tables don't capture.

5. Can you self-inject confidently? Both pen formats are easy, but if there is needle anxiety, the Wegovy pen and Mounjaro KwikPen are similarly designed. Vial-based generics require slightly more dexterity.

Only after those five questions do we land on a specific brand and starting dose. The medication is the easy part. The supervision is what determines whether it works.

The Long-Term View: Why Cost Matters Even More Than It Looks

One thing patients often don't think about until I raise it: the cost difference compounds dramatically over years, not just months.

The current clinical consensus is that GLP-1 therapy for obesity is best considered an indefinite treatment for most patients, similar to how we treat hypertension or hyperlipidaemia. About 70–80% of patients who stop the medication regain most of their lost weight within 12–18 months.

So if we project out 5 years of treatment at maintenance dose:

• Generic semaglutide vial: ~₹77,400 total
• Poviztra 2.4 mg (Emcure–Novo): ~₹5,39,940 total
• Wegovy 2.4 mg: ~₹9,84,000 total
• Mounjaro 15 mg: ~₹15,46,860 total

The difference between Poviztra and Mounjaro over 5 years is roughly ₹10 lakh. The difference between Wegovy and Mounjaro is around ₹5.6 lakh. The difference between generic semaglutide and Mounjaro is approximately ₹14.7 lakh.

I am not arguing that the cheapest option is always right. I am arguing that the cost should be discussed honestly, projected realistically, and weighed against the marginal clinical benefit. For most patients in my clinic — even relatively affluent NRI patients consulting from abroad — the answer is that Wegovy or supervised generic semaglutide delivers excellent results at a sustainable cost, and Mounjaro is reserved for the specific scenarios I outlined above.

What Will Change in the Next 2–3 Years

This pricing landscape is not static. Three things will shift the calculation:

1. Wegovy will get even cheaper. As semaglutide generics expand in India, Novo Nordisk will likely cut Wegovy prices again to defend market share. Expect another 20–30% reduction over the next 12 months.

2. Oral semaglutide (Rybelsus) will become a serious alternative. The post-patent oral formulation is already cheaper than injectable Wegovy, and may suit patients with needle aversion. See my Rybelsus vs Ozempic comparison for the full picture.

3. Tirzepatide patent will eventually expire — but not soon. Indian manufacturers are reportedly preparing tirzepatide generics for launch around 2027–2028 if patent challenges succeed, but Lilly's patent extends to approximately 2036 under current protection. Realistically, Mounjaro pricing won't shift significantly until the late 2020s at the earliest.

For now, in May 2026, the decision is what it is. And for the patient sitting in front of me, cost is — honestly — usually the deciding factor.

Frequently Asked Questions